$53.9 Million is the total value of Alerce Investment Management, L.P.'s 7 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMWL | AMERICAN WELL CORPcl a | $27,219,000 | +2.6% | 6,300,773 | 0.0% | 50.52% | +12.4% | |
| ANNX | ANNEXON INC | $7,370,000 | +38.1% | 1,954,978 | 0.0% | 13.68% | +51.3% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $4,678,000 | +1.9% | 2,227,500 | 0.0% | 8.68% | +11.7% | |
| AADI BIOSCIENCES INC | $4,617,000 | -27.4% | 374,785 | 0.0% | 8.57% | -20.5% | ||
| ALRN | AILERON THERAPEUTICS INC | $4,318,000 | -49.3% | 16,609,449 | 0.0% | 8.01% | -44.4% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $4,034,000 | -7.8% | 126,270 | 0.0% | 7.49% | +1.1% | |
| AKBA | AKEBIA THERAPEUTICS INC | $1,642,000 | -50.8% | 4,652,561 | 0.0% | 3.05% | -46.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-04
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMERICAN WELL CORP | 12 | Q3 2023 | 62.9% |
| ANNEXON INC | 12 | Q3 2023 | 35.9% |
| AKEBIA THERAPEUTICS INC | 12 | Q3 2023 | 31.6% |
| ASSEMBLY BIOSCIENCES INC | 12 | Q3 2023 | 8.7% |
| AADI BIOSCIENCES INC | 9 | Q3 2023 | 24.1% |
| AILERON THERAPEUTICS INC | 8 | Q3 2022 | 14.4% |
| GLOBAL BLOOD THERAPEUTICS IN | 8 | Q3 2022 | 23.4% |
| AILERON THERAPEUTICS INC | 4 | Q3 2023 | 2.3% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 5.2% |
View Alerce Investment Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-04 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-09 |
| 13F-HR | 2021-11-15 |
View Alerce Investment Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.